Advocate Outlines Resources for Chronic Myeloid Leukemia Population

Commentary
Video

Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.

In a conversation with CancerNetwork® at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Claire Saxton, MBA, described various resources that may offer guidance to patients with chronic myeloid leukemia (CML) as they receive treatment for their disease.

Saxton, the executive vice president of Insights and Impact at Cancer Support Community, listed a few patient advocacy organizations that can lend financial and mental health support to those who are undergoing therapy for CML. Beyond her organization, Saxton highlighted the Leukemia & Lymphoma Society and the CML Buster Foundation as groups that can assist patients with CML in the long term.

The Leukemia & Lymphoma Society aims to find a cure for leukemia, lymphoma, and multiple myeloma while improving patient quality of life through focus areas such as advancing health equity, improving clinical trial access, and offering patient financial assistance.1 This organization has initiated efforts to help increase federal research funds and expedite the review and approval process of new treatments for those with CML. Additionally, the CML Buster Foundation defines its purpose as an organization to “define, fund, create and maintain the tools of empowerment essential for the wellbeing of the [United States] CML community.”2

Transcript:

This is a long treatment journey. There is a huge impact [on the patient's] life, [their] family's life, and also on [their] mental health. Reach out for resources. It can be hard to find them initially, but there are a number of patient advocacy groups like Cancer Support Community, Leukemia & Lymphoma Society [LLS], and the [CML Buster Foundation] who are here and ready to help with financial counselors, support groups, and access to mental health professionals. Those are the kinds of things that are going to help give [them] the support that [they] need to get through [CML] in the long term.

References

  1. The LLS mission. Leukemia & Lymphoma Society. Accessed June 12, 2024. https://tinyurl.com/yck4hdjx
  2. CML Buster Foundation. GuideStar. Accessed June 12, 2024. https://tinyurl.com/yjx5y88h
Related Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Related Content